---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-318853"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2026-07-28T11:13:43+00:00"
generated_at: "2026-07-28T11:15:17.438366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife

## Summary
- Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.
- GAAP operating income flat at $14M; GAAP EPS $0.09 (down from $0.26).
- Full year 2026 guidance raised: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09.
- Announced definitive agreement to acquire BioLife Solutions, strengthening cell therapy position.
- Cash and marketable securities $810M at June 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-318853
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2026-07-28T11:13:43+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/0001193125-26-318853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/rgen-20260728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-318853
- JSON: https://secwatch.observer/filing/0001193125-26-318853.json
- Plain text: https://secwatch.observer/filing/0001193125-26-318853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.